Fate Therapeutics (FATE) Non Operating Income (2012 - 2026)

Fate Therapeutics has reported Non Operating Income for 15 years, with the latest figure at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 51.16% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (down 61.33% YoY), and the FY2025 full-year result was $11.4 million, down 52.57% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.8 million, down from $2.3 million in the prior quarter.
• The five-year high for Non Operating Income was $9.8 million in Q2 2023, with the low at $1.8 million in Q1 2026.
• Historically, Non Operating Income has averaged $5.5 million across 5 years, with a median of $4.7 million in 2024.
• Annual changes were most pronounced in 2022 — Non Operating Income jumped 958.61% — and 2025, when it plunged 75.54%.
• Fate Therapeutics' Non Operating Income stood at $8.1 million in 2022, then tumbled by 50.93% to $4.0 million in 2023, then jumped by 142.73% to $9.6 million in 2024, then sank by 75.54% to $2.3 million in 2025, then fell by 23.86% to $1.8 million in 2026.
• The last three Non Operating Income figures came in at $1.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.